# Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's Disease

> **NCT06459297** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 105 (actual)

## Conditions studied

- Ulcerative Colitis
- Crohn's Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06459297
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-24
- **Primary completion:** 2025-12-09
- **Final completion:** 2025-12-09
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06459297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06459297, "Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06459297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*